There are disclosed novel 3-amino(and substituted amino)-hydroxy (and dihydroxy)-1,2,3,4-tetrahydrocarbazoles having positive inotropic activity and methods and compositions for the use thereof in treating the failing heart in mammals afflicted with congestive heart failure.
Aza-tetrahydrocarbazole compound 12b showed the most potent hypoglycemic activity with a 45% increase in glucose consumption when compared to the solvent control, which had approximately 1.2-fold higher activity than the positive control compounds (metformin and ZG02). An investigation of the potential mechanism indicated that 12b may exhibit hypoglycemic activity via activation of the AMPK pathway. Metabolic